This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Cartesian Therapeutics, Inc. (RNAC) Moves 9.9% Higher: Will This Strength Last?
by Zacks Equity Research
Cartesian Therapeutics, Inc. (RNAC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Teladoc (TDOC) Moves 14.4% Higher: Will This Strength Last?
by Zacks Equity Research
Teladoc (TDOC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Exelixis (EXEL) Surges 7.4%: Is This an Indication of Further Gains?
by Zacks Equity Research
Exelixis (EXEL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Strength Seen in Nektar (NKTR): Can Its 12.1% Jump Turn into More Strength?
by Zacks Equity Research
Nektar (NKTR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
RGC Resources (RGCO) Surges 9.1%: Is This an Indication of Further Gains?
by Zacks Equity Research
RGC Resources (RGCO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Strength Seen in Mobileye (MBLY): Can Its 11.6% Jump Turn into More Strength?
by Zacks Equity Research
Mobileye (MBLY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Sarepta Therapeutics (SRPT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of -1,077.14% and 6.68%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Voyager Therapeutics (VYGR) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of -68.57% and 68.81%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
GSK (GSK) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Glaxo (GSK) delivered earnings and revenue surprises of 11.32% and 4.04%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Intra-Cellular (ITCI) Surges 14.9%: Is This an Indication of Further Gains?
by Zacks Equity Research
Intra-Cellular (ITCI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Cartesian Therapeutics, Inc. (RNAC) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Cartesian Therapeutics, Inc. (RNAC) delivered earnings and revenue surprises of 11.54% and 93.55%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Cartesian Therapeutics, Inc. (RNAC) Moves 26.9% Higher: Will This Strength Last?
by Zacks Equity Research
Cartesian Therapeutics, Inc. (RNAC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Cartesian Therapeutics, Inc. (RNAC) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Cartesian Therapeutics, Inc. (RNAC) delivered earnings and revenue surprises of 166.67% and 457.42%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Amicus Therapeutics (FOLD) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of 100% and 4.90%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stock Roundup: GSK, CVAC Revise Agreement, Updates From MRNA, RNAC & More
by Zacks Equity Research
GSK and CureVac (CVAC) are in the spotlight following a restructuring of their vaccine agreement.
Cartesian (RNAC) MG Study Meets Goals, Stock Down on Other Updates
by Zacks Equity Research
Cartesian (RNAC) announced that the phase IIb study in MG patients has achieved its primary endpoints. However, the stock nosedives following an equity financing announcement.
Cartesian (RNAC) Up as FDA Grants RMAT Tag to Descartes-08
by Zacks Equity Research
The FDA bestows RMAT designation to Cartesian's (RNAC) lead pipeline candidate, Descartes-08, for treating myasthenia gravis. Shares rise.
What Makes Cartesian Therapeutics, Inc. (RNAC) a New Buy Stock
by Zacks Equity Research
Cartesian Therapeutics, Inc. (RNAC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts Think Cartesian Therapeutics, Inc. (RNAC) Could Surge 141%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 141% upside potential for Cartesian Therapeutics, Inc. (RNAC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts Believe Cartesian Therapeutics, Inc. (RNAC) Could Rally 146.24%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Cartesian Therapeutics, Inc. (RNAC) points to a 146.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Down -30.75% in 4 Weeks, Here's Why You Should You Buy the Dip in Cartesian Therapeutics, Inc. (RNAC)
by Zacks Equity Research
Cartesian Therapeutics, Inc. (RNAC) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Cartesian Therapeutics, Inc. (RNAC) Loses -24.65% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
Cartesian Therapeutics, Inc. (RNAC) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Emergent Biosolutions (EBS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -1,100% and 5.94%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?